<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">chemicallytech</journal-id><journal-title-group><journal-title xml:lang="en">Fine Chemical Technologies</journal-title><trans-title-group xml:lang="ru"><trans-title>Тонкие химические технологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2410-6593</issn><issn pub-type="epub">2686-7575</issn><publisher><publisher-name>MIREA – Russian Technological University (RTU MIREA).</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.32362/2410-6593-2019-14-2-70-77</article-id><article-id custom-type="elpub" pub-id-type="custom">chemicallytech-208</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CHEMISTRY AND TECHNOLOGY OF INORGANIC MATERIALS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ХИМИЯ И ТЕХНОЛОГИЯ НЕОРГАНИЧЕСКИХ МАТЕРИАЛОВ</subject></subj-group></article-categories><title-group><article-title>Lanthanum Complex with Neridronic Acid: Synthesis and Properties</article-title><trans-title-group xml:lang="ru"><trans-title>Комплекс лантана с неридроновой кислотой: синтез и свойства</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Галанцев</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Galantsev</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант кафедры химии и технологии редких и рассеянных элементов, наноразмерных и композиционных материалов им. К.А. Большакова, Институт тонких химических технологий им. М.В. Ломоносова ФГБОУ ВО «МИРЭА – Российский технологический университет»; заместитель генерального директора ООО «Скайбиохим»</p><p>119571, Россия, Москва, пр-т Вернадского, д. 86</p><p>141090, Россия, Московская обл., г. Королёв, мкрн. Юбилейный, ул. Маяковского, 2</p></bio><bio xml:lang="en"><p>Postgraduate Student, K.A. Bolshakov Chair of Chemistry and Technology of Rare and Scattered Elements, Nanoscale and Composite Materials, M.V. Lomonosov Institute of Fine Chemical Technologies, MIREA – Russian Technological University; Deputy General Director of LLC Skybiochem</p><p>86, Vernadskogo pr., Moscow, 119571, Russia</p><p>2, Mayakovsky St., microdistrict Yubileiny, Korolev, Moscow region, 141090, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дробот</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Drobot</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор химических наук, профессор кафедры химии и технологии редких и рассеянных элементов, наноразмерных и композиционных материалов им. К.А. Большакова, </p><p>119571, Россия, Москва, пр-т Вернадского, д. 86</p></bio><bio xml:lang="en"><p>D.Sc. (Chemistry), Professor, K.A. Bolshakov Chair of Chemistry and Technology of Rare and Dispersed Elements, Nanoscale and Composite Materials</p><p>86, Vernadskogo pr., Moscow 119571, Russia</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дороватовский</surname><given-names>П. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Dorovatovsky</surname><given-names>P. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>заместитель начальника отдела синхротронных экспериментальных станций Курчатовского комплекса синхротронного излучения и нанотехнологий</p><p>123182, Россия, Москва, пл. Академика Курчатова, д. 1</p></bio><bio xml:lang="en"><p>Deputy Head of the Department of Synchrotron Experimental Stations of the Kurchatov Complex of Synchrotron Radiation and Nanotechnologies</p><p>1, Akademika Kurchatova sq.., Moscow, 123182, Russia</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хрусталев</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Khrustalev</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор химических наук, заведующий кафедрой неорганической химии Российского университета дружбы народов (РУДН), Директор Объединенного института химических исследований РУДН</p><p>117198, Москва, ул. Миклухо-Маклая, д. 6</p></bio><bio xml:lang="en"><p>D.Sc. (Chemistry), Head of the Chair of Inorganic Chemistry, Peoples’ Friendship University of Russia (RUDN), Director of the Joint Institute of Chemical Research of RUDN</p><p>6, Miklukho-Maklaya st., Moscow, 117198, Russia</p></bio><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>МИРЭА – Российский технологический университет;&#13;
ООО «Скайбиохим»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>MIREA – Russian Technological University, Moscow, 119571, Russia;&#13;
LLC Skybiochem, Moscow oblast, Korolev, 141090, Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>МИРЭА – Российский технологический университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>MIREA – Russian Technological University, Moscow, 119571, Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Национальный исследовательский центр «Курчатовский институт»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Research Center Kurchatov Institute, Moscow, 123182, Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Национальный исследовательский центр «Курчатовский институт»;&#13;
Российский университет дружбы народов (РУДН)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Research Center Kurchatov Institute, Moscow, 123182, Russia;&#13;
Peoples' Friendship University of Russia (RUDN), Moscow, 117198, Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>20</day><month>05</month><year>2019</year></pub-date><volume>14</volume><issue>2</issue><fpage>70</fpage><lpage>77</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Galantsev A.V., Drobot D.V., Dorovatovsky P.V., Khrustalev V.N., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Галанцев А.В., Дробот Д.В., Дороватовский П.В., Хрусталев В.Н.</copyright-holder><copyright-holder xml:lang="en">Galantsev A.V., Drobot D.V., Dorovatovsky P.V., Khrustalev V.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.finechem-mirea.ru/jour/article/view/208">https://www.finechem-mirea.ru/jour/article/view/208</self-uri><abstract><p>Currently, various amino bisphosphonates are widely used in the treatment of many bone diseases. One of the most well-known complex compounds of neridronic acid (6-amino-1-hydroxyhexylidene-1,1- bisphosphonic acid) is sodium neridronate – a bisphosphonate, which is used to treat osteogenesis and Paget's disease. However, there is no data on compounds of neridronic acid with rare earth elements. A new complex of lanthanum with 6-amino-1-hydroxyhexylidene-1,1-bisphosphonic acid (I) was obtained and characterized by various physicochemical methods (chemical analysis, IR spectroscopy, solid-phase 31P NMR spectroscopy, optical microscopy, PCA, DTA). According to the research data the complex I has the composition {La[(H3N-(CH2)5-C(OH)(PO2(OH))2]2(H2O)2}[OH]·H2O and represents the coordination 1D-polymer due to two bridged phosphonic groups with lanthanum atoms in a tetragonal-antiprismatic environment. In a crystal, polymer chains form a 3D-frame porous structure by means of strong hydrogen bonds O─H ··· O and N─H ··· O with endless channels, available to include a variety of inorganic anions or small organic molecules. A study under the microscope showed that the sample is needle crystals (thin rods) of different lengths. The particle size distribution was obtained by laser diffraction, and the average particle size was determined: 50 µm in length and 2.5 µm in thickness.</p></abstract><trans-abstract xml:lang="ru"><p>В настоящее время различные аминобисфосфонаты широко применяются при лечении многих костных заболеваний. Одним из наиболее известных комплексных соединений неридроновой кислоты (6-амино-1-гидроксигексилиден-1,1-бисфосфоновая кислота) является неридронат натрия – бисфосфонат, который используется для лечения остеогенеза и болезни Педжета. Однако нет данных о соединениях неридроновой кислоты с редкоземельными элементами. В ходе работы получен ранее не описанный комплекс лантана с 6-амино-1-гидроксигексилиден-1,1-бисфосфоновой кислотой (I). Он охарактеризован различными физико-химическими методами (химический анализ, ИК-спектроскопия, твердофазная 31P ЯМР-спектроскопия, оптическая микроскопия, РСА, ДТА). По данным проведенных исследований комплекс I имеет состав {La[(H3N-(CH2)5-C(OH)(PO2(OH))2]2(H2O)2}[OH]·H2O и представляет координационный 1D-полимер за счет двух мостиковых фосфоновых групп с атомами лантана, находящимися в тетрагонально-антипризматическом окружении. В кристалле полимерные цепочки образуют 3D-каркасную пористую структуру посредством сильных водородных связей O─H···O и N─H···O с бесконечными каналами, доступными для включения разнообразных неорганических анионов или малых органических молекул. Изучение под микроскопом показало, что образец представляет собой игольчатые кристаллы (тонкие стержни) различной длины. Методом лазерной дифракции получено распределение частиц по размеру и определен средний размер частиц – 50 мкм в длину и 2.5 мкм в толщину.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>бисфосфонат</kwd><kwd>неридроновая кислота</kwd><kwd>неридронат лантана</kwd><kwd>рентгеноструктурные данные</kwd><kwd>размер частиц</kwd></kwd-group><kwd-group xml:lang="en"><kwd>bisphosphonate</kwd><kwd>neridronic acid</kwd><kwd>lanthanum neridronate</kwd><kwd>X-ray data</kwd><kwd>particle size</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Loehrer P.J., Williams S.D., Einhorn L.H. Testicular cancer: the quest continues // J. Natl. Cancer Inst. 1988. V. 80. № 17. P. 1373–1382. https://doi.org/10.1093/jnci/80.17.1373.</mixed-citation><mixed-citation xml:lang="en">Loehrer P.J., Williams S.D., Einhorn L.H. Testicular cancer: the quest continues. J. Natl. Cancer Inst. 1988; 80(17):1373-1382. https://doi.org/10.1093/jnci/80.17.1373.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Williams S.D., Birch R., Einhorn L.H., Irwin L., Greco F.A. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide // N. Engl. J. Med. 1987. V. 316. P. 1435–1440. DOI:10.1056/NEJM198706043162302.</mixed-citation><mixed-citation xml:lang="en">Williams S.D., Birch R., Einhorn L.H., Irwin L., Greco F.A. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N. Engl. J. Med. 1987; 316:1435-1440. DOI:10.1056/NEJM198706043162302.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bosl G.J., Geller N.L., Bajorin D., Leitner S..P, Yagoda A., Golbey R.B., Scher H., Vogelzang N.J., Auman J., Carey R. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good prognosis germ cell tumors // J. Clin. Oncol. 1988. V. 6. № 8. P. 1231–1238. DOI:10.1200/JCO.1988.6.8.1231.</mixed-citation><mixed-citation xml:lang="en">Bosl G.J., Geller N.L., Bajorin D., Leitner S..P, Yagoda A., Golbey R.B., Scher H., Vogelzang N.J., Auman J., Carey R. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good prognosis germ cell tumors. J. Clin. Oncol. 1988; 6(8):1231-1238. DOI:10.1200/JCO.1988.6.8.1231.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Klenner T., Wingen F., Keppler B.K., Krempien B. and Schmahl D. Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies? // J. Cancer Res. Clin. Oncol. 1990. V. 116. № 4. P. 341–350.</mixed-citation><mixed-citation xml:lang="en">Klenner T., Wingen F., Keppler B.K., Krempien B. and Schmahl D. Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies? J. Cancer Res. Clin. Oncol. 1990; 116(4):341-350.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Galeano A., Berge M.R., Keppler B.K. Activity of two platinum-linked phosphonic acids against autochthonous rat colorectal cancer as well as in two human colon-cancer cell lines // J. Cancer Chemother. Pharmacol. 1992. V. 30. № 2. P. 131–138.</mixed-citation><mixed-citation xml:lang="en">Galeano A., Berge M.R. and Keppler B.K. Activity of two platinum-linked phosphonic acids against autochthonous rat colorectal cancer as well as in two human colon-cancer cell lines. J. Cancer Chemother. Pharmacol. 1992; 30(2):131-138.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ringe .JD., Fardellone P., Kruse H.P., Amling M., van der Geest S.A., Möller G. Value of a new ﬁxed-combination pack of bisphosphonate, calcium and vitamin D in the therapy of osteoporosis // Drugs &amp; Aging. 2009. V. 26. № 3. P. 241– 253. doi:10.2165/00002512-200926030-00005.</mixed-citation><mixed-citation xml:lang="en">Ringe J.D., Fardellone P., Kruse H.P., Amling M., van der Geest S.A., Möller G. value of a new ﬁxed-combination pack of bisphosphonate, calcium and vitamin D in the therapy of osteoporosis. Drugs &amp; Aging. 2009; 26(3):241-253. doi:10.2165/00002512-200926030-00005.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Simon J.A., Lewiecki E.M., Smith M.E. Patient preference for once-weekly alendronate 70 mg versus oncedaily alendronate 10 mg: a multicenter randomized, open-label, crossover study // Clin. Ther. 2002. V. 24. № 11. P. 1871–1886. https://doi.org/10.1016/S0149-2918(02)80085-6.</mixed-citation><mixed-citation xml:lang="en">Simon J.A., Lewiecki E.M., Smith M.E. Patient preference for once-weekly alendronate 70 mg versus oncedaily alendronate 10 mg: a multicenter randomized, openlabel, crossover study. Clin. Ther. 2002; 24(11):1871-1886. https://doi.org/10.1016/S0149-2918(02)80085-6.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ringe J.D., van der Geest S.A.P., Möller G. Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: an approach to improving correct intake and drug adherence // Drugs &amp; Aging. 2006. V. 23(7). P. 569–578. DOI: 10.2165/00002512-200623070-00003.</mixed-citation><mixed-citation xml:lang="en">Ringe J.D., van der Geest S.A.P., Möller G. Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: an approach to improving correct intake and drug adherence. Drugs &amp; Aging 2006; 23(7):569-578. DOI:10.2165/00002512-200623070-00003.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Amghouz Z., García J.R., García-Granda S., Clearﬁeld A., Fernández J.R. Lanthanide phosphonates: Synthesis, thermal stability and magnetic characterization // J. Alloys and Compounds. 2012. V. 536. S499–S503.</mixed-citation><mixed-citation xml:lang="en">Amghouz Z., García J.R., García-Granda S., Clearﬁeld A., Fernández J.R. Lanthanide phosphonates: Synthesis, thermal stability and magnetic characterization. J. Alloys and Compounds. 2012; 536:S499-S503.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Chmielewska E., Kafarski P. Synthetic procedures leading towards aminobisphosphonates // Molecules. 2016. 21(11). P. 1474. https://doi.org/10.3390/molecules21111474.</mixed-citation><mixed-citation xml:lang="en">Chmielewska E., Kafarski P. Synthetic procedures leading towards aminobisphosphonates. Molecules. 2016; 21(11):1474. https://doi.org/10.3390/molecules21111474.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Battye G.G., Kontogiannis L., Johnson O., Powell H.R., Leslie A.G.W. iMOSFLM: a new graphical interface for diﬀraction-image processing with MOSFLM // Acta Cryst. 2011. D67. P. 271–281. https://doi.org/10.1107/S0907444910048675.</mixed-citation><mixed-citation xml:lang="en">Battye G.G., Kontogiannis L., Johnson O., Powell H.R., Leslie A.G.W. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Cryst. 2011; D67:271-281. https://doi.org/10.1107/S0907444910048675.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Evans P. Scaling and assessment of data quality // Acta Cryst. 2006. D62. P. 72–82. https://doi.org/10.1107/S0907444905036693.</mixed-citation><mixed-citation xml:lang="en">Evans P. Scaling and assessment of data quality. Acta Cryst. 2006; D62:72-82. https://doi.org/10.1107/S0907444905036693.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Sheldrick G.M. Crystal structure reﬁnement with SHELXL // Acta Cryst. 2015. C71. P. 3–8. https://doi.org/10.1107/S2053229614024218.</mixed-citation><mixed-citation xml:lang="en">Sheldrick G.M. Crystal structure reﬁnement with SHELXL. Acta Cryst. 2015; C71:3-8. https://doi.org/10.1107/S2053229614024218.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
